Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer

Featuring perspectives from Dr Melissa Johnson, including the following topics: Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCLC) (0:00) Efficacy and safety with datopotamab deruxtecan for previously treated NSCLC (15:45) Antitumor activity with and current status of CEACAM5-targeted therapy for relapsed NSCLC (30:24) Evolution of drug development and clinical research (37:56) Key findings with sacituzumab govitecan for NSCLC (41:59) Telisotuzumab vedotin for patients with NSCLC and MET expression (48:44) Recent findings with tumor treating fields for metastatic NSCLC after disease progression on platinum-based therapy (50:49) Other novel antibody-drug conjugates under investigation for NSCLC (55:26) Case: A woman in her mid 50s with recurrent extensive-stage small cell lung cancer who developed pneumonitis on ifinatamab deruxtecan (59:05) Case: A woman in her early 60s with complete response to dose-reduced patritumab deruxtecan (1:00:15) CME information and select publications